Kawasaki Disease: Laboratory Findings and an Immunopathogenesis on the Premise of a "Protein Homeostasis System"

Yonsei Medical Journal

Volumn 53, Issue 2, 2012, Pages 262-275

  Lee, Kyung Yil ^a   Rhim, Jung Woo ^a   Kang, Jin Han ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Coronary artery lesions; Intravenous immunoglobulin; Kawasaki disease; Laboratory parameters; Non responders; Pathogenesis; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CYTOKINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PROTEIN; PROTEIN ANTIBODY;

ADAPTIVE IMMUNITY; ARTERY LESION; ARTICLE; CELL ACTIVATION; CELL DAMAGE; CORONARY ARTERY; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE DURATION; ENDOTHELIUM CELL; FEVER; HOST CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LABORATORY TEST; LEUKOCYTE COUNT; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEUTROPHIL COUNT; NONHUMAN; PROTEIN BINDING; PROTEIN HOMEOSTASIS; T LYMPHOCYTE; THROMBOCYTE COUNT; TISSUE INJURY; TISSUE REPAIR;

ANIMALS; CORONARY ARTERY DISEASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 84863140887     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2012.53.2.262     Document Type: Article

References (102)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967;16:178-222.
2. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33.
3. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease.A 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85.
4. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9.
5. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978;61:100-7.
6. Amano S, Hazama F, Kubagawa H, Tasaka K, Haebara H, Hamashima Y. General pathology of Kawasaki disease.On the morphological alterations corresponding to the clinical manifestations. Acta Pathol Jpn 1980;30:681-94.
7. Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, Rowley AH. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001;184:940-3.
8. Rowley AH, Shulman ST, Mask CA, Finn LS, Terai M, Baker SC, et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis 2000;182:1183-91.
9. Choi IH, Chwae YJ, Shim WS, Kim DS, Kwon DH, Kim JD, et al. Clonal expansion of CD8+ T cells in Kawasaki disease. J Immunol 1997;159:481-6.
10. Furuno K, Yuge T, Kusuhara K, Takada H, Nishio H, Khajoee V, et al. CD25+CD4+ regulatory T cells in patients with Kawasaki disease. J Pediatr 2004;145:385-90.
11. Galeotti C, Bayry J, Kone-Paut I, Kaveri S V. Kawasaki disease:aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev 2010;9:441-8.
12. Kim DS. Kawasaki disease. Yonsei Med J 2006;47:759-72.
13. Lee KY, Han JW, Lee JS. Kawasaki disease may be a hyper immune reaction of genetically susceptible children to variants of normal environmental flora. Med Hypotheses 2007;69:642-51.
14. Burns JC, Glodé MP. Kawasaki syndrome. Lancet 2004;364: 533-44.
15. Yeung RS. Kawasaki disease: update on pathogenesis. Curr Opin Rheumatol 2010;22:551-60.
16. Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther 2010;8:197-203.
17. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237-40.
18. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomo-masa T, et al. Prediction of intravenous immunoglobulin unre-sponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12.
19. Park YW, Han JW, Hong YM, Ma JS, Cha SH, Kwon TC, et al. Epidemiological features of Kawasaki disease in Korea, 2006-2008. Pediatr Int 2011;53:36-9.
20. Nakamura Y, Yashiro M, Uehara R, Sadakane A, Chihara I, Aoyama Y, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. J Epidemiol 2010;20:302-7.
21. Huang WC, Huang LM, Chang IS, Chang LY, Chiang BL, Chen PJ, et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics 2009;123:e401-5.
22. Kushner HI, Macnee RP, Burns JC. Kawasaki disease in India: increasing awareness or increased incidence? Perspect Biol Med 2009;52:17-29.
23. Kim SH, Kim KH, Kim DS. Clinical characteristics of Kawasaki disease according to age at diagnosis. Indian Pediatr 2009;46: 585-90.
24. Yeung RS. Phenotype and coronary outcome in Kawasaki's disease. Lancet 2007;369:85-7.
25. Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfeld JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008;153:117-21.
26. Youn YS, Lee KY, Hwang JY, Rhim JW, Kang JH, Lee JS, et al. Difference of clinical features in childhood Mycoplasma pneu-moniae pneumonia. BMC Pediatr 2010;10:48.
27. Li AM, Ng PC. Severe acute respiratory syndrome (SARS) in neonates and children. Arch Dis Child Fetal Neonatal Ed 2005; 90:F461-5.
28. Dentinger CM. Emerging infections: hepatitis A. Am J Nurs 2009;109:29-33.
29. Rhim JW, Lee KY, Youn YS, Kang JH, Kim JC. Epidemiologi-cal and clinical characteristics of childhood pandemic 2009 H1N1 virus infection: an observational cohort study. BMC Infect Dis 2011;11:225.
30. Powell DA, Hunt WG. Tuberculosis in children: an update. Adv Pediatr 2006;53:279-322.
31. Sheehy SH, Angus BJ. Malaria: severe, life-threatening. Clin Evid (Online) 2011. pii: 0913.
32. Lee KY, Hong JH, Han JW, Lee JS, Lee BC, Burgner D. Features of Kawasaki disease at the extremes of age. J Paediatr Child Health 2006;42:423-7.
33. Pannaraj PS, Turner CL, Bastian JF, Burns JC. Failure to diagnose Kawasaki disease at the extremes of the pediatric age range. Pediatr Infect Dis J 2004;23:789-91.
34. Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics 2003;112:495-501.
35. Holman RC, Curns AT, Belay ED, Steiner CA, Effer PV, Yorita KL, et al. Kawasaki syndrome in Hawaii. Pediatr Infect Dis J 2005;24:429-33.
36. Onouchi Y. Molecular genetics of Kawasaki disease. Pediatr Res 2009;65:46R-54R.
37. Onouchi Y, Tamari M, Takahashi A, Tsunoda T, Yashiro M, Na-kamura Y, et al. A genomewide linkage analysis of Kawasaki disease: evidence for linkage to chromosome 12. J Hum Genet 2007;52:179-90.
38. Burgner D, Davila S, Breunis WB, Ng SB, Li Y, Bonnard C, et al. A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PLoS Genet 2009;5:e1000319.
39. Chi H, Huang FY, Chen MR, Chiu NC, Lee HC, Lin SP, et al. ITPKC gene SNP rs28493229 and Kawasaki disease in Taiwanese children. Hum Mol Genet 2010;19:1147-51.
40. Kim JJ, Hong YM, Sohn S, Jang GY, Ha KS, Yun SW, et al. A genome-wide association analysis reveals 1p31 and 2p13.3 as susceptibility loci for Kawasaki disease. Hum Genet 2011;129: 487-95.
41. Burns JC. Kawasaki Disease update. Indian J Pediatr 2009;76: 71-6.
42. Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yas-hiro M, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008;40:35-42.
43. Kuo HC, Yang KD, Juo SH, Liang CD, Chen WC, Wang YS, et al. ITPKC single nucleotide polymorphism associated with the Kawasaki disease in a Taiwanese population. PLoS One 2011;6: e17370.
44. Kato H, Fujimoto T, Inoue O, Kondo M, Koga Y, Yamamoto S, et al. Variant strain of Propionibacterium acnes: a clue to the aetiology of Kawasaki disease. Lancet 1983;2:1383-8.
45. Shinomiya N, Takeda T, Kuratsuji T, Takagi K, Kosaka T, Tatsu-zawa O, et al. Variant Streptococcus sanguis as an etiological agent of Kawasaki disease. Prog Clin Biol Res 1987;250:571-2.
46. Abe J, Kotzin BL, Jujo K, Melish ME, Glode MP, Kohsaka T, et al. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci U S A 1992;89:4066-70.
47. Iwanaga M, Takada K, Osato T, Saeki Y, Noro S, Sakurada N. Kawasaki disease and Epstein-Barr virus. Lancet 1981;1:938-9.
48. Burns JC, Geha RS, Schneeberger EE, Newburger JW, Rosen FS, Glezen LS, et al. Polymerase activity in lymphocyte culture supernatants from patients with Kawasaki disease. Nature 1986; 323:814-6.
49. Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005;191:499-502.
50. Lidar M, Lipschitz N, Langevitz P, Shoenfeld Y. The infectious etiology of vasculitis. Autoimmunity 2009;42:432-8.
51. Sepp E, Julge K, Vasar M, Naaber P, Björksten B, Mikelsaar M. Intestinal microfora of Estonian and Swedish infants. Acta Pae-diatr 1997;86:956-61.
52. Adlerberth I, Carlsson B, de Man P, Jalil F, Khan SR, Larsson P, et al. Intestinal colonization with Enterobacteriaceae in Pakistani and Swedish hospital-delivered infants. Acta Paediatr Scand 1991;80:602-10.
53. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gamma globulin for Kawasaki disease. Lancet 1984;2:1055-8.
54. Hicks RV, Melish ME. Kawasaki syndrome; Rheumatic complains and analysis of salicylate therapy. Arthritis Rheum 1979;22:621-2.
55. Lee KY, Han JW, Hong JH, Lee HS, Lee JS, Whang KT. Inflammatory processes in Kawasaki disease reach their peak at the sixth day of fever onset: laboratory profiles according to duration of fever. J Korean Med Sci 2004;19:501-4.
56. Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gerso-ny W, Vetter VL, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007;356:663-75.
57. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991;33:805-10.
58. Lee KY, Han JW, Lee HS, Hong JH, Hahn SH, Lee JS, et al. Epidemiologic study of Kawasaki disease at a single hospital in Daejeon, Korea (1987 through 2000). Pediatr Infect Dis J 2004; 23:52-5.
59. Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 2000;137:177-80.
60. Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6.
61. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and re-treatment in Kawasaki disease. Pediatr Cardiol 2003;24:145-8.
62. Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007;166:131-7.
63. Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, et al. Analysis of potential risk factors associated with non response to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 2008;27:155-60.
64. Kim SK, Han JY, Rhim JW, Oh JH, Han JW, Lee KY, et al. Limitation of prediction on intravenous immunoglobulin responsiveness in Kawasaki disease. Korean J Pediatr Infect Dis 2010;17: 169-76.
65. Kelley-Hedgepeth A, Lloyd-Jones DM, Colvin A, Matthews KA, Johnston J, Sowers MR, et al. Ethnic differences in C reactive protein concentrations. Clin Chem 2008;54:1027-37.
66. Jibiki T, Terai M, Kurosaki T, Nakajima H, Suzuki K, Inomata H, et al. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease. Eur J Pediatr 2004;163:229-33.
67. Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, et al. A multi center prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006;149:336-41.
68. Yeo JS, Choi JW. Effectiveness of medium-dose intravenous immunoglobulin (1 g/kg) in the treatment of Kawasaki disease. Korean Circ J 2010;40:81-5.
69. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-93.
70. Lee KY, Lee HS, Hong JH, Han JW, Lee JS, Whang KT. High-dose intravenous immunoglobulin down regulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease. J Trop Pediatr 2005;51: 98-101.
71. Lee KY, Han JW, Lee JS, Whang KT. Alteration of biochemical profles after high-dose intravenous immunoglobulin administration in Kawasaki disease. Acta Paediatr 2002;91:164-7.
72. Lee KY, Kim DU, Lee HS, Jang PS, Kim YH, Kim JT, et al. The effects of high-dose intravenous immunoglobulin on plasma protein and lipid levels in the patients with Kawasaki disease. Korean J Pediatr 2006;49:1348-53.
73. Lee K Y, Lee JS. Immunoglobulin G has a role for systemic protein modulation in vivo: a new concept of protein homeostasis. Med Hypotheses 2006;67:848-55.
74. Terai M, Honda T, Yasukawa K, Higashi K, Hamada H, Kohno Y. Prognostic impact of vascular leakage in acute Kawasaki disease. Circulation 2003;108:325-30.
75. Hwang JY, Lee KY, Rhim JW, Youn YS, Oh JH, Han JW, et al. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease. Arch Dis Child 2011;96:1088-90.
76. Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993; 123:657-9.
77. Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr Infect Dis J 2004;23:463-4.
78. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105:E78.
79. Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infiximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008;153:833-8.
80. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9.
81. Lee TJ, Kim KH, Chun JK, Kim DS. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J 2008;49:714-8.
82. Mori M, Imagawa T, Katakura S, Miyamae T, Okuyama K, Ito S, et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol 2004;14:43-7.
83. Shulman ST, Tanz RR. Group A streptococcal pharyngitis and immune-mediated complications: from diagnosis to management. Expert Rev Anti Infect Ther 2010;8:137-50.
84. Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. Lancet Infect Dis 2009;9:281-90.
85. Olsen RJ, Shelburne SA, Musser JM. Molecular mechanisms underlying group A streptococcal pathogenesis. Cell Microbiol 2009;11:1-12.
86. Bryant PA, Robins-Browne R, Carapetis JR, Curtis N. Some of the people, some of the time: susceptibility to acute rheumatic fever. Circulation 2009;119:742-53.
87. Guilherme L, Kalil J. Rheumatic fever and rheumatic heart disease: cellular mechanisms leading autoimmune reactivity and disease. J Clin Immunol 2010;30:17-23.
88. Lloyd S, Mead S, Collinge J. Genetics of prion disease. Top Curr Chem 2011;305:1-22.
89. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5.
90. Tveita AA. The danger model in deciphering autoimmunity. Rheumatology (Oxford) 2010;49:632-9.
91. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009;22:240-73.
92. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011;30:16-34.
93. Schneider F, Tomek W, Gründker C. Gonadotropin-releasing hormone (GnRH) and its natural analogues: a review. Theriogenology 2006;66:691-709.
94. Shruti K, Shrey K, Vibha R. Micro RNAs:tiny sequences with enormous potential. Biochem Biophys Res Commun 2011;407: 445-9.
95. Macias ES, Pereira FA, Rietkerk W, Safai B. Superantigens in dermatology. J Am Acad Dermatol 2011;64:455-72.
96. Bran GM, Goessler UR, Hormann K, Riedel F, Sadick H. Keloids: current concepts of pathogenesis (review). Int J Mol Med 2009;24:283-93.
97. Mucida D, Cheroutre H. The many face-lifts of CD4 T helper cells. Adv Immunol 2010;107:139-52.
98. Lee K Y. Pediatric respiratory infections by Mycoplasma pneu-moniae. Expert Rev Anti Infect Ther 2008;6:509-21.
99. Lee KY, Rhim JW, Kang JH. Hyperactive immune cells (T cells) may be responsible for acute lung injury in influenza virus infections: a need for early immune-modulators for severe cases. Med Hypotheses 2011;76:64-9.
100. Kil HR, Lee JH, Lee KY, Rhim JW, Youn YS, Kang JH. Early corticosteroid treatment for severe pneumonia caused by 2009 H1N1 influenza virus. Crit Care 2011;15:413.
101. Lehman TJ, Warren R, Gietl D, Mahnovski V, Prescott M. Variable expression of Lactobacillus casei cell wall-induced coronary arteritis: an animal model of Kawasaki's disease in selected inbred mouse strains. Clin Immunol Immunopathol 1988;48:108-18.
102. Schulte DJ, Yilmaz A, Shimada K, Fishbein MC, Lowe EL, Chen S, et al. Involvement of innate and adaptive immunity in a murine model of coronary arteritis mimicking Kawasaki disease. J Immunol 2009;183:5311-8.